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Abstract
Background: Critical illness myopathy (CIM) and polyneuropathy (CIP) are a common complication of critical illness.
Both cause intensive-care-unit-acquired (ICU-acquired) muscle weakness (ICUAW) which increases morbidity and delays
rehabilitation and recovery of activities of daily living such as walking ability. Focused physical rehabilitation of people
with ICUAW is, therefore, of great importance at both an individual and a societal level. A recent systematic Cochrane
review found no randomised controlled trials (RCT), and thus no supporting evidence, for physical rehabilitation
interventions for people with defined CIP and CIM to improve activities of daily living. Therefore, the aim of our study is
to compare the effects of an additional physiotherapy programme with systematically augmented levels of mobilisation
with additional in-bed cycling (as the parallel group) on walking and other activities of daily living.
Methods/design: We will conduct a prospective, rater-masked RCT of people with ICUAW with a defined
diagnosis of CIM and/or CIP in our post-acute hospital. We will randomly assign patients to one of two parallel
groups in a 1:1 ratio and will use a concealed allocation. One intervention group will receive, in addition to
standard ICU treatment, physiotherapy with systematically augmented levels of mobilisation (five times per week,
over 2 weeks; 20 min each session; with a total of 10 additional sessions). The other intervention group will
receive, in addition to standard ICU treatment, in-bed cycle sessions (same number, frequency and treatment
time as the intervention group).
Standard ICU treatment includes sitting balance exercise, stretching, positioning, and sit-to-stand training, and
transfer training to get out of bed, strengthening exercise (in and out of bed), and stepping and assistive
standing exercises.
Primary efficacy endpoints will be walking ability (defined as a Functional Ambulation Category (FAC) level of ≥3) and
the sum score of the Functional Status Score for the Intensive Care Unit (FSS-ICU) (range 0–22 points) assessed by a
blinded tester immediately after 2 weeks of additional therapy.
Secondary outcomes will include assessment of sit-to-stand recovery, overall limb strength (Medical Research
Council, MRC) and grip strength, the Physical Function for the Intensive Care Unit Test-Scored (PFIT-S), the
EuroQol 5 Dimensions (EQ-5D) questionnaire and the Reintegration to Normal Living Index (RNL-Index)
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assessed by a blinded tester.
We will measure primary and secondary outcomes with blinded assessors at baseline, immediately after 2 weeks of
additional therapy, and at 3 weeks and 6 months and 12 months after the end of the additional therapy intervention.
Based on our sample size calculation 108 patients will be recruited from our post-acute ICU in the next 3 to 4 years.
Discussion: This will be the first RCT comparing the effects of two physical rehabilitation interventions for people with
ICUAW due to defined CIP and/or CIM to improve walking and other activities of daily living. The results of this trial will
provide robust evidence for physical rehabilitation of people with CIP and/or CIP who often require long-term care.
Trial registration: We registered the study on 6 April 2016 before enrolling the first patient in the trial at the German
Clinical Trials Register (www.germanctr.de) with the identifier DRKS00010269. This is the first version of the protocol
(FITonICU study protocol).
Keywords: Physical rehabilitation, ICU-acquired muscle weakness, Activities of daily living
Background
Critical illness myopathy (CIM) and polyneuropathy (CIP)
are common results of critical illness that frequently occur
together. Both cause so-called intensive-care-unit-ac-
quired (ICU-acquired) muscle weakness (ICUAW). Such
acquired muscle weakness is characterised by a profound
weakness that is greater than normally expected from
prolonged bed rest and, therefore, designated as clinically
detected weakness in critically ill patients in whom there
is no plausible aetiology other than critical illness [1–3].
The weakness of limb muscles significantly limits activ-
ities, such as sit-to stand, and assistance in transfers is
often required [3–6]. This in turn increases morbidity and
delays rehabilitation and recovery of walking [7–9]. Al-
though full recovery has been reported in approximately
50% of people with ICUAW, improvement is related to
the severity of the condition, e.g. people with severe weak-
ness may take months to improve, or even remain severely
affected [3, 10]. Focused physical rehabilitation of people
with ICUAW is, therefore, of great importance. There is
practical evidence that physical rehabilitation of patients
can be implemented with few adverse effects [1, 11, 12].
Recently, appropriate assessments were developed and de-
scriptions of suitable physical intervention strategies were
described in the medical literature [1, 9, 11, 13–16]. Until
now many of the described therapies investigated people
in the acute stage of ICU treatment [17] with only a few
trials considering patients who are so-called chronically
critically ill [18] and in the post-acute phase or people in
the post-ICU phase [18–20]. There is, therefore, still an
urgent need for effective therapy and rehabilitation in the
long-term after intensive care, e.g. to improve physical
function [20].
The need for a trial on rehabilitation interventions for
people in the post-acute phase with ICUAW
As it seems clear that physical activity may be a promis-
ing intervention to address functional challenges for
people with ICUAW due to a defined CIP and/or CIM,
it is surprising that a recent systematic Cochrane review
found no RCTs that examined the effects of physical re-
habilitation interventions for people with ICUAW and
defined CIP and/or CIM [21]. Several key questions
need to be answered. Firstly, is one of two tailored, add-
itional physical interventions more effective in helping
people with ICUAW and defined CIP and/or CIM to im-
prove activities of daily living and walking? Secondly,
does the range of possible benefits include strength and
quality of life, immediately after intervention and on
follow-up? Thirdly, what is the optimal and effective
physical intervention prescription for people in the post-
acute ICU with ICUAW and defined CIP and/or CIM?
Objective
The objective of the Fitness and mobility training in
patients with Intensive Care Unit-acquired muscle weak-
ness (FITonICU) study is, therefore, to describe the ef-
fects of an additional physiotherapy programme, with
systematically augmented levels of mobilisation, com-
pared with additional in-bed cycling on walking and
other activities of daily living. The null hypothesis is that
there is no statistically significant difference in the pri-
mary outcomes for the applied additional interventions.
We chose these comparators because both mobilisa-
tion and in-bed cycling are physical rehabilitation inter-
ventions that are commonly used clinically and seem
feasible and suitable for these chronically critically ill
patients in the post-acute ICU setting. Examples here
include (additional) in-bed cycling often being used in
critically ill patients on ICU [22] and also in the post-
acute phase [18] and a physiotherapy programme with
augmented levels of mobilisation is likely to be desirable
as mobilisation is often used in the rehabilitation of
chronically critically ill patients [3].
We will use a parallel-group randomised controlled
trial (RCT) design to investigate the effects of these two
different physical rehabilitation interventions for people
with ICUAW due to defined CIP and/or CIM.
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Methods/design
Study design
This is a assessor-blinded, parallel-group, single-centre
RCT of people with ICUAW with a defined diagnosis of
CIM and/or CIP based on a protocol prepared according
to the SPIRIT Statement (www.spirit-statement.org) [23]
(see Additional file 1 and for the SPIRIT figure see Fig. 1).
The study will be conducted at the post-acute ICUs
and the weaning units in one large specialised hospital
(Klinik Bavaria Kreischa, Germany).
Prior to the intervention, patients will be randomised in
a 1:1 ratio into one of two intervention parallel groups.
The one experimental group will receive, in addition to
standard ICU treatment, physiotherapy with systematically
augmented levels of mobilisation (five times per week,
over 2 weeks; each session will last 20 min; with a total of
10 additional sessions). The other group will receive in
addition to standard ICU treatment in-bed bicycle ses-
sions (with the same number, frequency and treatment
time as the intervention group).
After receiving ethical approval and registration of the
study we started recruiting in our hospital in 2016 and
the final assessments including follow-up will be made
in about 2020.
Screening process
We will enter all patients with the diagnosis of a defined
CIP and/or CIM into our screening log. Subsequently,
the patient will be screened for eligibility with the inclu-
sion and exclusion criteria as outlined in Table 1 and
Fig. 2. We will fully inform eligible patients and/or their
caregivers about the study, and we will assign an identifi-
cation number to the patient. Patients and/or their care-
givers are then asked to provide informed consent. In
the event that a potential participant does not meet the
inclusion criteria, we will not retain identifiable informa-
tion on that patient. We will report all reasons for exclu-
sion in a flow chart. After providing informed consent
we will record all medical and neurological information
at baseline in a Case Report Form (Table 2).
Two of the investigators will conduct all baseline
assessments (see Table 2 for details). Those study as-
sessors will not be involved in treating patients or
with administration of the intervention and will re-
main fully blinded to the patient’s group allocation
throughout the whole trial.
Informed consent
Written informed consent for study participation will
be obtained at 1 to 7 days after admission at our
department.
Participants will be informed that successful comple-
tion of the baseline tests is required prior to randomisa-
tion to an intervention group.
Eligibility criteria
Participants will have ICUAW due to defined CIP and/
or CIM (for details see Table 1). The diagnosis of CIP
and/or CIM will be confirmed by a neurologist accord-
ing to published criteria [9, 24] at ICU prior to admis-
sion or after admission to our post-acute ICU.
Outcome measures
Primary efficacy endpoints are walking ability and activ-
ities of daily living.
We define our endpoint walking ability with a category
of ≥3 on the Functional Ambulation Categories (FAC;
Fig. 1 Standard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) figure for the schedule of enrolment, interventions and
assessments. Time points: t0: baseline; t1: 2 weeks post treatment; t2: 3-
week follow-up (FU1); t3: 6- and 12-month follow-ups (FU2); t4: 12-
month follow-up (FU3). Abbreviations: FITonICU, Fitness and mobility
training in patients with Intensive Care Unit-acquired muscle weakness;
FU follow-up; T time point; FAC Functional Ambulation Categories; FSS-
ICU Functional Status Score for the Intensive Care Unit Scored; STS ability
to stand up from a chair independently; MRC sum score Medical Research
Council (sum score of muscle strength of the upper (shoulder, elbow
and wrist) and the lower limb (hip, knee and ankle)); PFIT-S Physical
Function for the Intensive Care Unit Test-Scored; EQ-5D EuroQol 5
Dimensions questionnaire; RNL-Index Reintegration to Normal Living Index
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0–5 score range) [25–27]. We use this scale to measure
walking ability because in a recent cohort study it has
been shown to be a very feasible tool to describe the
ability to walk in different settings, such as ICU, post-
acute rehabilitation and also at follow-up [26].
We will use the Functional Status Score for the Inten-
sive Care Unit Scored (FSS-ICU; 0–35 score range) [28]
to measure elementary activities of daily living. We will
use this scale because in a recent cohort study the FSS-
ICU was also very feasible, reliable and also predictive
(for important aspects of daily living) in different set-
tings and stages such as ICU, post-acute rehabilitation
and post-acute care [26].
Our secondary endpoints comprise scales with a com-
prehensive spectrum of impairments, activities and
participation for this population (see Table 2). We will
measure the ability to stand up by documenting the abil-
ity to stand up from a standardised chair independently
(STS) [27]. We will measure muscle strength of the
upper (shoulder, elbow and wrist) and lower limb (hip,
knee and ankle) using the Medical Research Council
(MRC) sum score and calculate and provide a MRC sum
score for the upper and also for the lower limbs [1, 27, 29].
We will measure the handgrip strength for both hands
using a hand dynamometer (Jamar handgrip dynamom-
eter; Sammons Preston Rolyan, Bolingbrook, IL, USA)
[27, 30–32]. We will use the Physical Function for the
Intensive Care Unit Test-Scored (PFIT-S) [33] to meas-
ure specific ICU impairments. We will assess quality of
life using the EQ-5D [34] and measure participation
with the Reintegration to Normal Living Index (RNL-
Index) [27, 35, 36]. All of these measures are frequently
used in research and/or clinical practice dealing with
this patient group. Table 2 gives a detailed overview of
the variables used at each time point of study and the
data collection schedule.
Assessment of safety and adverse events
At each assessment the following parameters will be sys-
tematically recorded: recurrent, fatal or nonfatal cardio-
vascular or cerebrovascular events; referral to an acute
hospital; and death. After each intervention, the treating
physiotherapist will record the presence of self-reported
pain, fatigue, dizziness and number and nature of falls,
and note any other adverse events. Additionally, oxygen
saturation, mean arterial pressure, and heart rate will be
documented for every therapy session.
Standardisation of assessments
Blinded assessors have systematically undergone compe-
tency training to ensure standardisation of data collec-
tion methods. This included theoretical learning about
the assessments, demonstration and practice on volun-
teers (patients with ICUAW in our post-acute ICU)
under the supervision of the study’s clinical research co-
ordinators. Successful completion of competency train-
ing was confirmed by a competency checklist.
Data collection
Masked outcome data are collected by blinded assessors
at baseline (T0), after 2 weeks of therapy (T1), after a 3-
week follow-up (FU1), at 6-month follow-up (FU2) and
at 12-month follow-up (FU3) (see Fig. 2 and Table 2).
Outcome data will be double-entered into two data
tables by masked researchers who have no knowledge of,
or access to, identifiable participant information or treat-
ment assignment. The two data entries are compared,
corrections made and also tested for inter-rater reliabil-
ity between the blinded assessors.
Randomisation and concealment of allocation
Each study participant will be randomly assigned to one of
two intervention groups, either the MOBILITY group or
the BEDCYC group. Allocation will be concealed within an
opaque sealed envelope (Fig. 2). The computer-generated
random allocation sequence list will be carried out (JM)
using a random-number generator (randomizer.org). As-
signments will be enclosed in sequentially numbered,
opaque, sealed envelopes and stored at the central study
centre. The persons who assess eligibility, obtain informed
consent and enrol patients in the trial (ST and KM) have
Table 1 Inclusion and exclusion criteria of study
Inclusion criteria
1. Patient is in the post-acute phase and chronically critically ill, defined as
more than 21 days ICU of treatment including mechanical ventilation,
and at least 14 days more in an existing critical situation with the need
for ICU treatment [27, 51, 52]
2. Acquired muscle weakness defined as a Medical Research Council
(MRC) sum score of <48 points [1]
3. Defined diagnosis of critical illness myopathy (CIM) and/or
polyneuropathy (CIP) confirmed by a neurologist according to
published diagnostic criteria for CIP/CIM [24]
4. Older than 18 years of age
5. Richmond Agitation Sedation Scale (RASS) score from −1 to 1 [53]
6. Written informed consent of the patient or their legal guardian has
been obtained
Exclusion criteria
1. Patients receiving palliative care
2. Comorbidities of the trunk or the lower limbs interfering with upright
posture and walking function (e.g. amputation or fracture of lower limb)
3. Other neuromuscular or neurological disease and/or syndromes causing
weakness in patients in the ICU (we will exclude patients with diseases
and syndromes causing weakness in patients in the ICU [9], due to
Guillain-Barré syndrome, myasthenia gravis, porphyria, Eaton-Lambert
syndrome, amyotrophic lateral sclerosis, vasculitic neuropathy, cervical
myelopathy and botulism)
4. Severe physical comorbidity before becoming critical ill (e.g. frailty
due to neurological conditions)
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no knowledge of group assignment. After recruitment, the
appropriate numbered, opaque, sealed envelope will be
opened and the randomisation information will be given to
the patient and therapists (but not to the outcome asses-
sors and not to the statistician performing the analysis).
Interventions
Patients will be randomly assigned to either the MOBIL-
ITY or the BEDCYC (see Fig. 2 and Table 2).
Patients in the MOBILITY group will receive, in
addition to standard treatment, 20 min physiotherapy
daily. This additional physiotherapy programme in-
cludes systematically augmented levels of therapy and
mobilisation (Table 3) five times per week, over 2
weeks. The MOBILITY programme contains 10 stan-
dardised exercises in hierarchical order (from low grade
to higher grade):
1. Turning from the one side to the other side when
lying in the supine position and alternate supine
bridging/buttock lift
2. Protracting hands and arms up and down the legs
while sitting
3. Reach and grasp objects from a table while sitting
4. Knee-bending while standing near the bed with
assistance
5. Sit-to-stand exercises as fast as possible
6. Balance exercises while standing without hand(rail)
support
7. Reach and grasp objects from a table while standing
8. Stepping while standing
9. Walking on a 10-m indoor floor
10.Climbing stairs
In every therapy session the highest possible of the
above-mentioned 10 standardised exercises will be se-
lected. For example, a patient who is able to sit on their
own will practice exercise #4, which is bending the knees
while standing near the bed with assistance. If the workout
of the selected exercise of the MOBILITY programme or
the starting position of the exercise is not possible the
preceding exercise will be selected by the therapist. For
example, a patient who is able to sit on their own but fails
to stand up and bend his knees while standing near the
bed with assistance, exercise #3 instead of #4 will be se-
lected and trained in therapy.
All 10 exercises will be trained by qualified and
instructed therapists and intensity increased progressively
Fig. 2 Flow chart of the Fitness and mobility training in patients with Intensive Care Unit-acquired muscle weakness (FITonICU) study design
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Table 2 Overview of enrolment, interventions and assessments of the Fitness and mobility training in patients with Intensive Care
Unit-acquired muscle weakness (FITonICU) study
Time point Enrolment
pretreatment
Allocation Baseline (T0) 2 weeks post
treatment (T1)
Daily
documentation
3-week follow-up (FU1) 6- and 12-month
follow-up (FU2–3)
Enrolment
Eligibility screening x
Informed consent x
Allocation x x
Interventions
Physiotherapy x x x x
Occupational x x x x
therapy
Other therapies (e.g. groups) x x x x
Additional x x
interventions x x
Primary outcome
FAC score x x x x x
FSS-ICU x x x x
Secondary outcomes
STS x x x x x
MRC sum score x x x
Grip strength x x x
PFIT-S x x
EQ-5D x x
RNL-Index x x
FU follow-up, T time point, FAC Functional Ambulation Categories, FSS-ICU Functional Status Score for the Intensive Care Unit Scored, STS ability to stand up from
a chair independently, MRC sum score Medical Research Council (sum score of muscle strength of the upper (shoulder, elbow and wrist) and the lower limb (hip,
knee and ankle)), PFIT-S Physical Function for the Intensive Care Unit Test-Scored, EQ-5D EuroQol 5 dimensions questionnaire, RNL-Index Reintegration to Normal
Living Index
Table 3 Overview of the schedule for increasing the intensity of every therapy session in the MOBILITY group
Session# Repetitions Increasea Sets Rest between sets (s)
1 As many as possibleb n.a. 2 120
2 As in previous session + increase At least by 1 2 120
3 As in previous session + increase At least by 1 2 120
4 As in previous session + increase At least by 1 2 120
5 As in previous session + increase At least by 1 3 90
6 As in previous session + increase At least by 1 4 90
7 As in previous session + increase At least by 1 4 90
8 As in previous session + increase At least by 1 4 60
9 As in previous session + increase At least by 1 4 60
10 As in previous session + increase At least by 1 4 45
aTherapists chose from our list of 10 standardised exercises the most demanding exercise for every session to adjust for individual differences and physical state
on the day of the session
bOne repetition minimum and a maximum of 10 repetitions even if more repetitions would be possible; if more than 10 repetitions are possible the task (e.g.
starting position) itself will be augmented; level 0 means the maximum of repetitions on the first day/first session
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according to Table 3. The therapists will document the
trained exercises, and total duration and intensity for each
single session. The therapy session will be paused/inter-
rupted or terminated if the patient (using continuously
monitoring):
 Has a heart rate below 60 or above 180 beats per
min for longer than 3 min
 Has a persistent SpO2 < 88% when lying or sitting
for longer than 3 min
 Has a systolic blood pressure below 100 mmHg or
above 180 mmHg for longer than 3 min
 Has a diastolic blood pressure below 50 mmHg or
above 110 mmHg for longer than 3 min
The adherence of the MOBILITY programme will be
documented in daily logs and reported.
All single exercises in the MOBILITY programme are
well-known and used routinely under different circum-
stances for the target patients in our department. Our
additional MOBILITY programme with systematically
augmented levels of mobilisation and therapy is, how-
ever, not described in the medical literature yet. For this
reason we underwent a pilot training programme testing
the feasibility of the MOBILITY programme in our de-
partment with all above-mentioned criteria. We found in
10 patients in this pilot training that the MOBILITY
programme might be feasible without any adverse event.
BEDCYC
The BEDCYC group will receive, in addition to standard
treatment, 20 min of in-bed cycle ergometer sessions
(the same number, frequency and treatment time as the
MOBILITY group) [22]. We chose in-bed cycling as
comparator to compare two true active and potentially
effective interventions. For instance Kho et al. recently
described the feasibility and safety of in-bed cycle ergo-
metry as part of routine ICU practice [22]. They
described 181 patients on ICU receiving a total of 541
cycling sessions and described a very low (0.2%) event
rate and concluded that the use of in-bed cycling as part
of routine physical therapy interventions in ICU patients
is feasible and appears to be safe [22]. We will use the
same in-bed cycle therapy approach as described earlier;
however, contrary to the CYCLE pilot protocol of Kho et
al. [37] we will use 20-min in-bed cycle ergometer ses-
sions instead of 30-min sessions. BEDCYC will be pro-
vided by two experienced therapists who are only
providing BEDCYC therapy but not the therapy to the
experimental group.
Adherence to the BEDCYC therapy will be docu-
mented in daily logs and reported.
To control for cointerventions (standard therapy) dur-
ing the intervention phase of the study (T0 to T1)
therapists will document the total duration and content
of both standard and additional therapy. Content will be
described for each 5-min block.
Criteria for discontinuing or modifying allocated
intervention in both groups
Therapy sessions will not occur if any of the following
conditions are present:
 Body temperature below 36 °C or above 38.5 °C
 Heart rate below 40 or above 130 beats per min
 Persistent SpO2 < 90% when lying or sitting
 Mean arterial pressure below 60 mmHg or above
110 mmHg
 Negative-pressure wound therapy
 Chest drainage systems
 Catecholamine medication (vasopressor/inotropes)
within the past 2 h
 Active myocardial ischemia or any unstable
arrhythmia
 Sedation or severe agitation (Richmond Agitation
and Sedation Scale score <1 or >2)
 Uncontrolled pain
 Rehabilitation goal has been changed to palliative care
 Rehabilitation team perception that therapy is not
appropriate despite absence of the above criteria
 Refusal of consent
Additional information
The standard care/treatment includes sitting balance
exercise, stretching, positioning, sit-to-stand training,
transfer training to get out of bed, strengthening exer-
cise (in and outside of bed), stepping and assistive stand-
ing exercises as described previously [38]. The standard
treatment will be about 45 min daily of individual phys-
ical therapy and the duration of therapy will be kept
equal in both intervention groups. Total time spent in
rehabilitative therapy will be recorded by so-called usual
care intervention logs to report the number of physio-
therapy and occupational therapy sessions received in
the first 2 weeks of the study (as part of the usual care
treatment). Information about medication and treatment
will be recorded at baseline. Length of stay in ICU and
the time spent in post-acute ICU and in rehabilitation
will be documented (in days).
As described above, physiotherapists will record in
every session the presence of self-reported pain, fatigue,
dizziness, number and nature of falls and note other
adverse events. The adherence to standard care will be
described in daily logs and reported.
Sample size
Until now, no trials and, therefore, no specific effect size
of the selected interventions for this specific population
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are present in the peer-reviewed literature. Our sample
size calculation of 45 patients per study arm is based on
a difference of 6 points in the primary endpoint of the
FSS-ICU sum score between the parallel groups after 2
weeks of treatment. We assume an alpha level of 5%, a
statistical power of 80% (beta = 20%) and a standard de-
viation (SD) of 10 using a two-sample t test for mean
differences. Our assumption is based on the theory that
the one experimental group achieves a mean of 22
points and the other group achieves a mean of 16 points
in the FSS-ICU test assuming a SD of 10 in the FSS-ICU
sum score and assuming that the rate of recovery of
walking ability will be 0.6 in the one and 0.4 in the other
group. We used the SAS (SAS Institute Inc., Cary, NC,
USA) power and sample size programme for our sample
size calculation. Because we consider a 20% dropout
rate, a total of 108 patients (54 per study arm) would be
enrolled to ensure 45 subjects in both intervention arms.
Recruitment
Based on our sample size calculation, 108 patients will
be recruited from our post-acute ICU over the time
course of 3 to 4 years. In a first cohort study in our
hospital we recruited 150 patients with ICUAW and a
diagnosis of CIM/CIP in approximately 18 months [26].
The research staff will follow the recruitment process
of a previous study [26] and will screen lists of patients
on a daily basis to recruit continuously and will monitor
recruitment. Recruitment statistics for every week will
be discussed to improve the recruitment and retention
procedure. Based on this the research team discusses up-
dates to recruitment and retention strategies if neces-
sary. Based on our experience from our previous study
we believe that it seems to be reasonable to recruit the
anticipated sample size in our trial within 3 to 4 years.
Statistical methods
We will conduct both intention-to-treat and per-protocol
analyses, with the intention-to-treat analysis being always
the primary analysis for the primary and secondary
outcomes.
Our descriptive statistics will include means and SDs,
medians and interquartile ranges for continuous vari-
ables, and the number and proportions for categorical
variables as appropriate [39].
We will compare the two intervention groups at base-
line regarding characteristics and demographics, using
two-tailed Student’s t tests or Fisher’s exact tests, as ap-
propriate. Variables that differ between the groups at
baseline will be considered as possible confounders and
adjusted for in subsequent analyses. The global alpha
level will be set at 0.05 for all comparisons. To avoid
multiplicity we will use a Tukey-Kramer alpha adjust-
ment for multiple comparisons of the same outcome.
Skewed data will be analysed with nonparametric test
alternatives (e.g. we will use the Mann-Whitney U test
instead of Student’s t tests if data are skewed).
For the primary endpoint, the FSS-ICU, we will test
the hypothesis that the sum score after 2 weeks of inter-
vention and at follow-up will be statistically different be-
tween groups. We will consider a minimum difference
of 5 points of the FSS-ICU sum score (range 0–35
points) between groups as being clinically important.
For the primary endpoint, walking ability, we will ana-
lyse the time to regain walking ability (defined as FAC
score ≥3) in a time-to-event analysis. We will calculate
the probability of regaining walking ability with the
Kaplan-Meier (KM, ‘survival analysis’) method [40] and
will provide KM plots as appropriate with 95% confi-
dence intervals (CI) including the number of partici-
pants at risk at each time. We will report median times
until regaining walking ability with 95% CI. The assump-
tions of KM analysis will be tested with the implemented
function of SAS/STAT 9.3 (SAS Institute Inc., Cary, NC,
USA). Cox regression analysis will be used to estimate
relative hazard rates of the intervention groups [41].
Time to event will be defined as the time difference be-
tween study entry (T0) and the date of reaching a FAC
score equal to 3, or the possible censoring dates of dis-
charge or treatment refusal or death, respectively. Data
will, therefore, be censored appropriately if patients are
discharged, refused treatment or died. We will use the
log-rank test to test statistically for differences between
the KM curves of the intervention groups [42]. We will
use a stepwise multivariable Cox regression analysis with
a variable selection to also take into account the influ-
ence of all dependent variables (PROC PHREG; best
subset analysis; SAS 9.3, SAS Institute Inc., Cary, NC,
USA) [41, 43]. The following dependent-variable cat-
egories will be analysed for their association with walk-
ing ability:
 Demographic variables at baseline (such as age and
sex)
 All clinical variables at baseline (such as muscle
strength, PFIT-S; Table 2) and
 Medical characteristics at baseline (such as diagnosis
and duration of primary illness)
All dependent (explanatory) variables will be first de-
scribed in a univariate analysis and then selected for a
multivariable model based on statistical significance
[44–46]. In this process an explanatory variable has to
be significant at the 0.2 level to be entered into the
multivariate model [43]. To remain in the multivariate
model an explanatory variable has to be significant at
the 0.1 level [43]. We will first select explanatory vari-
ables from a list of all univariate analysis with the
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highest global chi-square score into our multivariable
model [43]. We will use a graphical inspection and
also evaluate whether the proportional hazard as-
sumption for an explanatory variable is met [41]. We
will, for the final model selection, compare the multi-
variate models (with remaining variables) on the glo-
bal score chi-square statistic (best subset selection)
and on the Akaike’s information criterion (AIC) per-
formed [43]. The aim of our analysis is to explain the
dependent variable (e.g. regaining walking function)
by a multivariate Cox proportional hazard model with
not too many variables (to prevent overfitting) [43].
The multivariate effects of explanatory variables in
the final model will be expressed as hazard ratios
(HR) with 95% CI [43]. We will use SAS/STAT 9.3
for all statistical procedures (SAS Institute Inc., Cary,
NC, USA).
We will do an interim analysis for efficacy and inef-
fectiveness after half the patients have completed our
study trial. The trial will be stopped if there is a statisti-
cally significant difference between the groups in one
direction at an alpha level of 0.05 at this time point of
recruitment.
Adverse event monitoring and reporting
All adverse events will be carefully monitored at every
level of the FITonICU study. A Data Safety Monitoring
Board provides oversight and meets after randomisa-
tion of every 20 newly recruited patients. All adverse
events are reported immediately to the responsible
physician and the board members are informed of all
adverse events.
The Data Safety Monitoring Board and the research
team (all authors) will be responsible for data safety and
for the confidentially of recruited patients. The confi-
dentiality of participants will be granted by using an-
onymous ID lists for all recruited patients. All patient
data will be maintained and stored confidentially on a
separate computer server.
The Data Safety Monitoring Board will do an interim
analysis for safety of every 20 included and treated pa-
tients. The trial will be stopped:
 If there is a statistically significant difference in
safety between the groups in one direction at an
alpha level of 0.05 at this time point of recruitment
 If one of the interventions is associated with
unexpected excessive adverse effects such as skin
ulcerations, pulmonary embolism or deep vein
thrombosis, or there are excessive withdrawals
 If the study recruitment is unsuccessful (e.g. 3
months without any recruitment) or
 If other situations occur that might justify stopping
this trial
Ethics and dissemination
The FITonICU study will be conducted in accordance
with the Helsinki Declaration. The study is noninvasive,
imposes no additional risk on patients, seems to have
enough power to detect meaningful determinants and
our protocol has been approved by the medical ethical
committees (ethical vote ‘Landesärztekammer Sachsen’
Germany; EK-BR-104/15-1). Furthermore, written informed
consent is obtained from all participants or, if necessary,
from a legal guardian (WS, UB and ST). We registered our
study on 6 April 2016 before enrolling the first patient in
the trial at the German Clinical Trials Register (www.-
germanctr.de/) with the identifier DRKS00010269.
We plan to disseminate the results of this study to the
scientific, medical and general public by publication in
national and international peer-reviewed journals, as
well as by presentations at conferences and meetings
with clinicians working with patients with ICUAW.
Authorship will follow the recommendations of the
International Committee of Journal Editors for author-
ship. No professional writers will be employed.
Discussion
The FITonICU study will be one of the first rater-
blinded RCTs comparing the effects of two active phys-
ical rehabilitation interventions for people with ICUAW
and defined CIP and/or CIM to improve walking and
other activities of daily living. The results of this trial
might help to close an obvious research gap for physical
rehabilitation of people with ICUAW [21].
Considering the lack of evidence-based rehabilitation,
and the high level of medical interest in the area of re-
habilitation of people who are chronically critically ill,
this trial will be a significant advance in physical re-
habilitation for people with ICUAW due to a defined
CIP and/or CIM.
Although descriptions of post-acute interventions and
long-term studies for people who are chronically critic-
ally ill do exist [18, 47–49], there are no RCTs that
measure the effects of potentially effective physical re-
habilitation interventions for people who are critically ill
with ICUAW on improvement in activities and physical
function [21]. This study will, therefore, determine
whether a specific physical intervention for people with
ICUAW is beneficial in the post-acute care of these
patients.
Limitations
One could argue that the lack of a true control group, e.g.
of standard or no additional physiotherapy, might be a
weakness of our trial protocol. We have, however, de-
signed this study to compare two potentially capable and
reasonable active physical rehabilitation interventions for
patients on ICU. The feasibility and safety of BEDCYC
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was established in previous studies [37] and is a promising
physical rehabilitation intervention for patients on ICU.
The efficacy and effectiveness relative to standard treat-
ment alone for BEDCYC will be investigated in other
RCTs [37, 50]. The MOBILITY intervention is not yet de-
scribed in the literature, but MOBILITY was tested over
several months at our department and seems a feasible
physical rehabilitation intervention for patients on ICU.
We decided not to introduce a ‘classical’ control group in
our study, because there is no such classical control treat-
ment in the ICU, but there is a need for effective therapy
to be conducted to explore the role of physical rehabilita-
tion interventions for people with CIP and CIM.
The second limitation is that this trial is planned to be
carried out as a single-centre study and can, therefore,
only be seen as a first or pilot study. This pilot trial is,
however, adequately powered and funded. Further RCTs
should, however, try to recruit further centres and hospi-
tals to increase the clinical knowledge about physical re-
habilitation interventions for people with ICUAW.
Trial status
Patient recruitment began on 15 April 2016 and is ex-
pected to continue for 3 to 4 years in total.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (PDF 43 kb)
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